<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01019863</url>
  </required_header>
  <id_info>
    <org_study_id>122752</org_study_id>
    <nct_id>NCT01019863</nct_id>
  </id_info>
  <brief_title>Study to Evaluate an Oxaliplatin-based Chemotherapy in Patients With Resistant or Relapsing Non-Hodgkin Lymphoma.</brief_title>
  <acronym>LNH-RGDOX</acronym>
  <official_title>Study to Evaluate an Oxaliplatin-based Chemotherapy in Patients With Resistant or Relapsing Non-Hodgkin Lymphoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the efficacy, tolerance, quality of life and cost effectiveness of the
      association of Oxaliplatin, Gemcitabine, Rituximab and Dexamethasone for treatment of
      patients with refractory or relapsing non-Hodgkin lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2008</start_date>
  <completion_date type="Anticipated">October 2011</completion_date>
  <primary_completion_date type="Anticipated">October 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate to RGDOx in patients with relapsing or refractory NHL</measure>
    <time_frame>Within 3 months after chemotherapy (6-8 cycles)</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Oxaliplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oxaliplatin associated with Rituxan,Gemcitabine, and Dexamethasone in patients with refractory or relapsed Non hodgkinien lymphoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>oxaliplatin 100mg/m2 + Rituxan 375 mg/m2 + Gemcitabine 1000mg/m2 every 2 weeks for 8 cycles</description>
    <arm_group_label>Oxaliplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients 18 years or above at the time of inclusion.

          2. Documented CD20+ NHL, refractory or relapsing after first line chemotherapy.

          3. No contraindication to Oxaliplatin, Gemcitabine, Dexamethasone or Rituximab.

        Exclusion Criteria:

          1. Other types of non-Hodgkin lymphoma

          2. Pregnancy and lactation.

          3. Patient unable to give written informed consent.

          4. Contra-indication ou intolerance to any of the components of the RGDOx chemotherapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rami Kotb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHUS Hopital Fleurimont</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anick Champoux, RN</last_name>
    <phone>819-346-1110</phone>
    <phone_ext>12811</phone_ext>
    <email>achampoux.chus@ssss.gouv.qc.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHA Hôpital de l'Enfant-Jésus</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Vallée, RN</last_name>
      <phone>418-649-0252</phone>
      <phone_ext>3115</phone_ext>
      <email>linda.vallee.cha@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Jean-François Larouche, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUS Hopital Fleurimont</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anick Champoux, Research coordinator</last_name>
      <phone>819-346-1110</phone>
      <phone_ext>12811</phone_ext>
      <email>achampoux.chus@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Rami Kotb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2009</study_first_submitted>
  <study_first_submitted_qc>November 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2009</study_first_posted>
  <last_update_submitted>January 11, 2011</last_update_submitted>
  <last_update_submitted_qc>January 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr Rami Kotb, hematologist</name_title>
    <organization>CHUS Hopital Fleurimont</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

